keyword
MENU ▼
Read by QxMD icon Read
search

tumor molecular subtype

keyword
https://www.readbyqxmd.com/read/29775690/molecular-subtyping-of-colorectal-cancer-recent-progress-new-challenges-and-emerging-opportunities
#1
REVIEW
Wei Wang, Raju Kandimalla, Hao Huang, Lina Zhu, Ying Li, Feng Gao, Ajay Goel, Xin Wang
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Similar to many other malignancies, CRC is a heterogeneous disease, making it a clinical challenge for optimization of treatment modalities in reducing the morbidity and mortality associated with this disease. A more precise understanding of the biological properties that distinguish patients with colorectal tumors, especially in terms of their clinical features, is a key requirement towards a more robust, targeted-drug design, and implementation of individualized therapies...
May 15, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29773414/hypofractionated-whole-breast-irradiation-with-or-without-boost-in-elderly-patients-clinical-evaluation-of-an-italian-experience
#2
Maria Carmen De Santis, Francesca Bonfantini, Francesca Di Salvo, Alba Fiorentino, Michela Dispinzieri, Mariangela Caputo, Serena Di Cosimo, Gabriella Mariani, Massimiliano Gennaro, Vito Cosentino, Milena Sant, Emanuele Pignoli, Riccardo Valdagni, Laura Lozza
PURPOSE: To examine local control, disease-free survival (DFS), and toxicity in elderly (≥ 65 years) breast cancer patients treated with hypofractionated radiotherapy (hypo-RT) with or without a boost to the tumor bed. PATIENTS AND METHODS: The study was conducted on 752 patients treated from April 2009 to February 2017. Patients received 42.4 Gy in 16 daily fractions (2.65 Gy per fraction). A boost was only administered in cases of grade 3 primary tumor and close or positive margins...
April 22, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29772837/conventional-pathology-versus-gene-signatures-for-assessing-luminal-a-and-b-type-breast-cancers-results-of-a-prospective-cohort-study
#3
Julia E C van Steenhoven, Anne Kuijer, Paul J van Diest, Joost M van Gorp, Marieke Straver, Sjoerd G Elias, Jelle Wesseling, Emiel Rutgers, Johanna N H Timmer-Bonte, Peter Nieboer, Tineke J Smilde, Alex Imholz, Charlotte F J M Blanken, Sabine Siesling, Thijs van Dalen
In this study, in estrogen receptor positive (ER+) early stage breast cancer patients who were considered candidates for 70-gene signature (70-GS, "MammaPrint") use, we compared molecular subtyping (MS) based on the previously validated 80-gene signature (80-GS, "BluePrint") versus surrogate pathological subtyping (PS). Between 1 January 2013 and 31 December 2015, 595 clinical intermediate risk ER+ early stage breast cancer patients were enrolled. Hormone receptor (HR) and HER2 receptor status were determined by conventional pathology using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH)...
May 17, 2018: Genes
https://www.readbyqxmd.com/read/29768500/clinically-relevant-inflammatory-breast-cancer-patient-derived-xenograft-derived-ex-vivo-model-for-evaluation-of-tumor-specific-therapies
#4
Bedrich L Eckhardt, Maria Gagliardi, LaKesla Iles, Kurt Evans, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Glauco Souza, Arvind Rao, Funda Meric-Bernstam, Naoto T Ueno, Geoffrey A Bartholomeusz
Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient survival. Like non-inflammatory breast cancer, IBC comprises multiple subtypes, with the triple-negative subtype being overrepresented. Although the current multimodality treatment regime of anthracycline- and taxane-based neoadjuvant therapy, surgery, and radiotherapy has improved the outcome of patients with triple-negative IBC, overall survival continues to be worse than in patients with non-inflammatory locally advanced breast cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29768052/options-for-treating-different-soft-tissue-sarcoma-subtypes
#5
Isabelle Ray-Coquard, Delphine Serre, Peter Reichardt, Javier Martín-Broto, Sebastian Bauer
Management of soft tissue sarcoma is increasingly subtype-dependent. Surgery is recommended for uterine leiomyosarcoma, with trabectedin being the preferred option for advanced disease when the treatment goal is long-term tumor stabilization. Liposarcoma subgroups are characterized by distinctive morphologies and genetics, different patterns of disease progression and clinical behavior, and variable responses to treatment. Genetic analysis of sarcomas has provided insights into pathogenesis with potential for developing new molecular targets...
May 2018: Future Oncology
https://www.readbyqxmd.com/read/29768051/the-key-role-of-pathology-surgery-and-radiotherapy-in-the-initial-management-of-soft-tissue-sarcoma
#6
Angelo Paolo Dei Tos, Sylvie Bonvalot, Rick Haas
Soft tissue sarcomas are a heterogeneous group of rare malignancies. The diagnostic gold standard is conventional histomorphology with integrated immunohistochemistry. Molecular genetic profiling has identified new subgroups of undifferentiated sarcomas involving genetic rearrangements with creation of fusion genes. Accurate classification of sarcomas is critical for appropriate clinical decision-making which should involve a multidisciplinary team. A preoperative biopsy is necessary to confirm a diagnosis...
May 2018: Future Oncology
https://www.readbyqxmd.com/read/29765563/targeted-therapies-in-the-management-of-locally-advanced-and-metastatic-pancreatic-cancer-a-systematic-review
#7
REVIEW
Anjali V Sheahan, Andrew V Biankin, Christopher R Parish, Levon M Khachigian
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29764444/molecular-and-clinical-characterization-of-ptpn2-expression-from-rna-seq-data-of-996-brain-gliomas
#8
Peng-Fei Wang, Hong-Qing Cai, Chuan-Bao Zhang, Yan-Michael Li, Xiang Liu, Jing-Hai Wan, Tao Jiang, Shou-Wei Li, Chang-Xiang Yan
BACKGROUND: Immune checkpoint inhibitors have been shown to promote antitumor immunity and achieve durable tumor remissions. However, certain tumors are refractory to current immunotherapy. These negative results encouraged us to uncover other therapeutic targets and strategies. PTPN2 (protein tyrosine phosphatase, non-receptor type 2) has been newly identified as an immunotherapy target. Loss of PTPN2 sensitizes the tumor to immunotherapy via IFNγ signaling. METHODS: Here, we investigated the relationship between PTPN2 mRNA levels and clinical characteristics in gliomas...
May 15, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29764408/congenital-rhabdomyosarcoma-a-different-clinical-presentation-in-two-cases
#9
Ida Russo, Virginia Di Paolo, Carmelo Gurnari, Angela Mastronuzzi, Francesca Del Bufalo, Pier Luigi Di Paolo, Angela Di Giannatale, Renata Boldrini, Giuseppe Maria Milano
BACKGROUND: Rhabdomyosarcoma (RMS), one of the most common soft tissue sarcomas of childhood, is very rare in the neonatal period (0.4-2% of cases). In order to gain a deeper understanding of this disease at such age, patient and tumor features, as well as treatment modality and outcome need to be reported. CASE PRESENTATION: We describe two cases with congenital RMS treated at Bambino Gesù Children's Hospital between 2000 and 2016. They represent only 2.24% of all RMS patients diagnosed during that period in our Institution; this data is in agreement with the incidence reported in the literature...
May 15, 2018: BMC Pediatrics
https://www.readbyqxmd.com/read/29763719/small-cell-carcinoma-of-the-urinary-bladder-a-clinicopathologic-and-immunohistochemical-analysis-of-81-cases
#10
Gang Wang, Li Xiao, Miao Zhang, Ashish M Kamat, Arlene Siefker-Radtke, Colin P Dinney, Bogdan Czerniak, Charles C Guo
Small cell carcinoma (SmCC) of the bladder is a rare disease. We retrospectively studied a large series of bladder SmCC from a single institution. The patients included 69 men and 12 women with a mean age of 68years. Most bladder SmCC were presented at advanced stage with tumors invading the muscularis propria and beyond (n=77). SmCC was pure in 27 cases and mixed with other histologic types in 54 cases, including urothelial carcinoma (UC) (n=32), UC in situ (n=26), glandular (n=14), micropapillary (n=4), sarcomatoid (n=4), and squamous (n=3), and plasmacytoid (n=1) features...
May 12, 2018: Human Pathology
https://www.readbyqxmd.com/read/29761914/molecular-features-in-young-vs-elderly-breast-cancer-patients-and-the-impacts-on-survival-disparities-by-age-at-diagnosis
#11
Mei-Xia Wang, Jun-Ting Ren, Lu-Ying Tang, Ze-Fang Ren
Young and elderly breast cancer patients are more likely to have a poorer outcome than middle-aged patients. The intrinsic molecular features for this disparity are unclear. We obtained data from the Cancer Genome Atlas (TCGA) on May 15, 2017 to test the potential mediation effects of the molecular features on the association between age and prognosis with a four-step approach. The relative contributions of the molecular features (PAM50 subtype, risk stratification, DNAm age, and mutations in TP53, PIK3CA, MLL3, CDH1, GATA3, and MAP3K1) to age disparities in survival were estimated by Cox proportional hazard models with or without the features...
May 15, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29758283/tgf-%C3%AE-fibronectin-and-integrin-%C3%AE-5%C3%AE-1-promote-invasion-in-basal-cell-carcinoma
#12
François Kuonen, Isabelle Surbeck, Kavita Y Sarin, Monique Dontenwill, Curzio Ruegg, Michel Gilliet, Anthony E Oro, Olivier Gaide
Basal cell carcinoma (BCC) is the most frequent human cancer and is becoming an important health problem in an ageing population. Based on their clinical and histological characteristics, thick BCC are typically divided into low-risk nodular and high-risk infiltrative subtypes, although the underlying mechanisms are poorly understood. We have identified molecular mechanisms that explain the aggressiveness of high-risk infiltrative BCC, with a potential direct clinical impact. In this study, we first show that fibroblasts, TGFβ and fibronectin are found preferentially in infiltrative human BCC...
May 11, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29754847/feasibility-of-classification-of-triple-negative-breast-cancer-by-immunohistochemical-surrogate-markers
#13
Sewha Kim, Byung-In Moon, Woosung Lim, Sanghui Park, Min Sun Cho, Sun Hee Sung
INTRODUCTION: Recently, Burstein et al identified 4 stable molecular subtypes of triple negative breast cancer (TNBC) by mRNA profiling: luminal androgen receptor (LAR), mesenchymal (MES), basal-like immune-activated (BLIA), and basal-like immune-suppressive (BLIS) types. The purpose of this study was to assess the feasibility of immunohistochemistry (IHC) surrogate panel in classifying the TNBC molecular subtypes using a large cohort of TNBC retrieved from a single institution. MATERIALS AND METHODS: IHC for androgen receptor [AR], claudin-3, E-cadherin, cytokeratin 5/6 [CK5/6], epidermal growth factor receptor [EGFR], indoleamine 2,3-dioxygenase 1 [IDO1], and Forkhead box C1 [FOXC1] were performed using the tissue microarray constructed from 200 TNBC samples...
March 23, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29753961/the-role-of-parp-inhibition-in-triple-negative-breast-cancer-unraveling-the-wide-spectrum-of-synthetic-lethality
#14
REVIEW
Marios Papadimitriou, Giannis Mountzios, Christos A Papadimitriou
Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers and is characterized by a lack of immunohistochemical expression of estrogen receptors (ER), progesterone receptors (PR) and HER2. TNBC is associated with poor long-term outcomes compared with other breast cancer subtypes. Many of these tumors are also basal-like cancers which are characterized by an aggressive biological behavior with a distant recurrence peak observed early at 3 years following diagnosis. Furthermore, metastatic TNBC bears a dismal prognosis with an average survival of 12 months...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29753110/inorganic-phosphate-transporters-in-cancer-functions-molecular-mechanisms-and-possible-clinical-applications
#15
REVIEW
Marco Antônio Lacerda-Abreu, Thais Russo-Abrahão, Robson de Queiroz Monteiro, Franklin David Rumjanek, José Roberto Meyer-Fernandes
Inorganic phosphate is one of the most essential nutrients for the maintenance of cell life. Because of its essential role in nutrient supplementation, the study of plasma membrane inorganic phosphate transporters in cancer biology has received much attention in recent years. Several studies suggest that these transporters are up-regulated in tumor cells and thus have been considered to be important promoters of tumor progression. Altered expression levels of inorganic phosphate transporters, such as NaPi-IIb (SLC34A2) and PiT-1 (SLC20A1), have been demonstrated...
May 9, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29752686/the-histone-deacetylase-inhibitor-obp-801-and-eribulin-synergistically-inhibit-the-growth-of-triple-negative-breast-cancer-cells-with-the-suppression-of-survivin-bcl-xl-and-the-mapk-pathway
#16
Hisako Ono, Yoshihiro Sowa, Mano Horinaka, Yosuke Iizumi, Motoki Watanabe, Mie Morita, Emi Nishimoto, Tetsuya Taguchi, Toshiyuki Sakai
PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup analysis in this clinical trial indicated the efficacy of eribulin in patients with TNBC. However, the prognosis of patients with TNBC is still poor due to various molecular characteristics. Therefore, there is an urgent need for a more effective treatment for the management of TNBC...
May 11, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29747153/molecular-characterization-of-colorectal-signet-ring-cell-carcinoma-using-whole-exome-and-rna-sequencing
#17
Jae-Yong Nam, Bo Young Oh, Hye Kyung Hong, Joon Seol Bae, Tae Won Kim, Sang Yun Ha, Donghyun Park, Woo Yong Lee, Hee Cheol Kim, Seong Hyeon Yun, Yoon Ah Park, Je-Gun Joung, Woong-Yang Park, Yong Beom Cho
BACKGROUND: Signet-ring cell carcinoma (SRCC) is a very rare subtype of colorectal adenocarcinoma (COAD) with a poor clinical prognosis. Although understanding key mechanisms of tumor progression in SRCCs is critical for precise treatment, a comprehensive view of genomic alterations is lacking. MATERIALS AND METHODS: We performed whole-exome sequencing of tumors and matched normal blood as well as RNA sequencing of tumors and matched normal colonic tissues from five patients with SRCC...
May 7, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29746612/clinical-significance-of-complex-glandular-patterns-in-lung-adenocarcinoma-clinicopathologic-and-molecular-study-in-a-large-series-of-cases
#18
Muyu Kuang, Xuxia Shen, Chongze Yuan, Haichuan Hu, Yang Zhang, Yunjian Pan, Chao Cheng, Difan Zheng, Lei Cheng, Yue Zhao, Xiaoting Tao, Yuan Li, Haiquan Chen, Yihua Sun
Objectives: To explore whether complex glandular patterns (CGPs) have a potential role in the clinical management of patients with lung adenocarcinoma. Methods: We included 356 patients with lung adenocarcinoma with available clinicopathologic information, gene mutations, and clinical outcomes for analysis. Results: We identified 54 (15.2%) CGP-predominant cases. The CGPs were associated with ALK rearrangement and HER2 mutation. Survival analysis showed that the clinical outcome of CGP-predominant patients was worse than that for acinar-predominant patients (overall survival [OS], 66...
May 9, 2018: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29743053/pdxliver-a-database-of-liver-cancer-patient-derived-xenograft-mouse-models
#19
Sheng He, Bo Hu, Chao Li, Ping Lin, Wei-Guo Tang, Yun-Fan Sun, Fang-You-Min Feng, Wei Guo, Jia Li, Yang Xu, Qian-Lan Yao, Xin Zhang, Shuang-Jian Qiu, Jian Zhou, Jia Fan, Yi-Xue Li, Hong Li, Xin-Rong Yang
BACKGROUND: Liver cancer is the second leading cause of cancer-related deaths and characterized by heterogeneity and drug resistance. Patient-derived xenograft (PDX) models have been widely used in cancer research because they reproduce the characteristics of original tumors. However, the current studies of liver cancer PDX mice are scattered and the number of available PDX models are too small to represent the heterogeneity of liver cancer patients. To improve this situation and to complement available PDX models related resources, here we constructed a comprehensive database, PDXliver, to integrate and analyze liver cancer PDX models...
May 9, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29739984/invasive-lobular-and-ductal-breast-carcinoma-differ-in-immune-response-protein-translation-efficiency-and-metabolism
#20
Tian Du, Li Zhu, Kevin M Levine, Nilgun Tasdemir, Adrian V Lee, Dario A A Vignali, Bennett Van Houten, George C Tseng, Steffi Oesterreich
Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer following invasive ductal carcinoma (IDC). ILC differs from IDC in a number of histological and clinical features, such as single strand growth, difficulty in detection, and frequent late recurrences. To understand the molecular pathways involved in the clinical characteristics of ILC, we compared the gene expression profiles of luminal A ILC and luminal A IDC using data from TCGA and utilized samples from METABRIC as a validation data set...
May 8, 2018: Scientific Reports
keyword
keyword
34448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"